Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $33.3 million.

  • Amphastar Pharmaceuticals' Non-cash Items fell 8025.18% to $33.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.3 million, marking a year-over-year decrease of 8025.18%. This contributed to the annual value of $4.9 million for FY2024, which is 9851.71% down from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Non-cash Items stood at $33.3 million for Q3 2025, which was down 8025.18% from $20.0 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Non-cash Items peaked at $327.2 million during Q4 2023, and registered a low of $500000.0 during Q4 2021.
  • Moreover, its 5-year median value for Non-cash Items was $20.0 million (2025), whereas its average is $81.0 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Non-cash Items plummeted by 9889.85% in 2021 and then skyrocketed by 579394.45% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Non-cash Items (Quarter) stood at $500000.0 in 2021, then surged by 1010.14% to $5.6 million in 2022, then soared by 5793.94% to $327.2 million in 2023, then tumbled by 98.52% to $4.9 million in 2024, then surged by 586.94% to $33.3 million in 2025.
  • Its last three reported values are $33.3 million in Q3 2025, $20.0 million for Q2 2025, and $46.4 million during Q1 2025.